Alethia Young sold $50k of BCYC
Chief Financial Officer at BICYCLE THERAPEUTICS PLC. 7,623 shares at an average of $6.62, traded Jan 2, 2026, filed Jan 6, 2026.
Score components
- +22RoleCFO
- +7Trade size$50k at market
- 0Share of holdings soldSold 8.0% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001918147-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | AGrant or award Ordinary Shares10b5-1 | +50,000 | $0.00 | $0 | 94,704 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -3,289 | $6.80 | $22k | 91,415 | Jan 6, 2026 |
| Jan 5, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -2,456 | $6.45 | $16k | 88,959 | Jan 6, 2026 |
| Jan 5, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -1,878 | $6.54 | $12k | 87,081 | Jan 6, 2026 |
| Jan 2, 2026 | AGrant or award Employee Stock Option (right to buy)derivative10b5-1 | +100,000 | $0.00 | $0 | 100,000 | Jan 6, 2026 |
Related signals
Other insiders at BICYCLE THERAPEUTICS PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | BICYCLE THERAPEUTICS PLC | Jennifer Scott Perry Chief Operating Officer | $1,339 356 shares | -0% | |
| 30Weak | BICYCLE THERAPEUTICS PLC | Michael Skynner CHIEF SCIENTIFIC OFFICER | $8,534 2,445 shares | -2% | |
| 45Moderate | BICYCLE THERAPEUTICS PLC | Kevin Lee CHIEF EXECUTIVE OFFICER | $27k 7,805 shares | -1% | |
| 37Weak | BICYCLE THERAPEUTICS PLC | Travis Alvin Thompson Chief Financial Officer | $3,381 972 shares | -1% | |
| 30Weak | BICYCLE THERAPEUTICS PLC | Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF | $6,319 1,814 shares | -2% | |
| 35Weak | BICYCLE THERAPEUTICS PLC | Robert Charles Swanton director | $12k 3,431 shares | -18% | |
| 15Weak | BICYCLE THERAPEUTICS PLC | Jennifer Scott Perry Chief Operating Officer | $5,313 1,500 shares | -2% | |
| 36Weak | BICYCLE THERAPEUTICS PLC | Michael Skynner CHIEF TECHNOLOGY OFFICER | $42k 6,311 shares | -4% | |
| 51Moderate | BICYCLE THERAPEUTICS PLC | Kevin Lee CHIEF EXECUTIVE OFFICER | $141k 21,314 shares | -3% | |
| 41Moderate | BICYCLE THERAPEUTICS PLC | Alistair Milnes CHIEF OPERATING OFFICER | $44k 6,660 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.